Small- Cell Lung Cancer
Conditions
Brief summary
The aim of this study is to evaluate the safety and efficacy of dendritic cells (DC) combined with cytokine-induced killer (CIK) cells treatment patients with Extensive-Stage Small-Cell Lung Cancer. Experimental adopted recombinant adenovirus-code MUC1 and Survivin transfected DC, which are used for DC-based immunotherapy. Based on the results of our previously preclinical research with DC combined with CIK cells, the investigators plan to perform the clinical trial.
Interventions
Sponsors
Affiliated Hospital to Academy of Military Medical Sciences
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 70 Years
Healthy volunteers
No
Inclusion criteria
* Histopathologically confirmed diagnosis of Small- Cell Lung Cancer * Age \>18 years at time of consent * Received standardized treatment of Small-Cell Lung Cancer * Interval between the last standardized treatment and DC/CIK treatment ≥ 4weeks * KPS (Karnofsky performance scale) \>60 * Patient's written informed consent * No severe viral or bacterial infections * Predicted survival \>3 months
Exclusion criteria
* Clinically relevant diseases or infections (HBV, HCV, HIV) * Females who are pregnant or nursing * Immunosuppressant treatment * Currently participating in another clinical trial * Unfit for participating in this clinical trial in investigators' opinions
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| objective rate response (CR+PR) as measured by RECIST criteria | 4 weeks after DC/CIK treatment] |
Secondary
| Measure | Time frame |
|---|---|
| number of participants with adverse events | 3 days within DC/CIK treatment |
Outcome results
None listed